【摘要】 目的:探讨度洛西汀对持续性躯体形式疼痛障碍(PSPD)的疗效、安全性及对生活质量的影响。方法:对85例PSPD患者予以度洛西汀60 mg/d,疗程8周。分别于治疗前、治疗2、4和8周时对患者进行疼痛视觉模拟量表(VAS)、汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)、健康调查简表(SF-36)以及治疗过程中出现的症状量表(TESS)评分。结果:VAS和HAMA评分治疗后2周起、HAMD评分治疗后4周起较治疗前明显下降(P<0.05或P<0.01);疗程结束时对焦虑和抑郁的有效率分别是69.1%和65.4%,SF-36总分和躯体疼痛、一般健康状况、精力、情感职能、精神健康等因子分较治疗前显著提高(P<0.05或P<0.01);常见不良反应为食欲减退,恶心和疲乏。结论:度洛西汀治疗PSPD安全有效,并能改善患者生活质量。更多还原

【Abstract】 Objective: To explore the efficacy and safety of duloxetine on persistent somatoform pain disorder( PSPD),and effects of these patients’ quality of life. Method: Eighty-five PSPD patients were treated with duloxetine 60 mg / d for 8 weeks. The patients were assessed with pain visual analogue scale( VAS),Hamilton anxiety scale( HAMA),Hamilton depression dcale( HAMD),and the Mos 36-item short form health survey( SF-36), treatment emergent symptom scale( TESS) before treatment and 2,4,8 weeks after,respectively. Results: The scores of VAS and HAMA since the second week,the scores of HAMD since the fourth week after treatment were significantly decreased than before treatment( P < 0. 05 or P < 0. 01). At the end of the course,the efficiencies of anxiety and depression were 69. 1% and 65. 4% respectively. The total score of SF-36 and those factor scores of bodily pain,general health,energy,emotional function,mental health and several were significantly increased than before treatment( P < 0. 05 or P < 0. 01). Common adverse reactions were loss of appetite,nausea and fatigue. Conclusion: Duloxetine is safe and effective on PSPD,and can improve the patients’ quality of life.更多还原